Yahoo · Nov 4, 2026
Is Regeneron Stock Increasing Your Market Risk?
For questions about this article or underlying research, email [email protected].
AB
NASDAQ · ABBV
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$294.83
Up+$8.83 (+3.09%)
Updated Nov 5, 2026, 6:31 AM
SID Score
7.0/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 410.09B
- P/E ratio
- 97.75
- Dividend yield
- 2.81%
- 52-week range
- $190.75 – $298.74
- Volume
- 8.44M
- Avg. volume
- 6.4M
Price performance · ABBV
ABBV price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
ABBV closed at $294.83 after 21 trading sessions, up 8.65% for the selected period.
- Last close
- $294.83
- Period change
- +8.65%
- Period low
- $271.36
- Period high
- $294.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $293.95 | $295.40 | $283.32 | $294.83 | 8.44M |
| Nov 3, 2026 | $288.69 | $291.322 | $284.70 | $286.00 | 5.37M |
| Nov 2, 2026 | $290.38 | $294.86 | $286.14 | $288.84 | 8.85M |
| Oct 30, 2026 | $292.00 | $298.74 | $291.01 | $294.89 | 6.9M |
| Oct 29, 2026 | $291.00 | $292.67 | $288.04 | $290.79 | 4.33M |
| Oct 28, 2026 | $282.93 | $288.80 | $281.225 | $285.99 | 3.11M |
| Oct 27, 2026 | $283.88 | $287.32 | $283.12 | $286.39 | 3.27M |
| Oct 26, 2026 | $287.05 | $289.586 | $285.18 | $286.74 | 4.52M |
| Oct 23, 2026 | $284.58 | $286.765 | $282.30 | $285.64 | 4.63M |
| Oct 22, 2026 | $284.57 | $285.76 | $278.01 | $285.19 | 6.17M |
| Oct 21, 2026 | $287.63 | $288.9999 | $282.15 | $284.80 | 4.39M |
| Oct 20, 2026 | $286.90 | $290.98 | $285.00 | $289.08 | 5.18M |
| Oct 19, 2026 | $284.23 | $287.9299 | $282.59 | $282.68 | 4.17M |
| Oct 16, 2026 | $283.61 | $286.64 | $282.955 | $285.42 | 5.78M |
| Oct 15, 2026 | $288.28 | $291.40 | $282.81 | $283.40 | 7.62M |
| Oct 14, 2026 | $277.00 | $285.3999 | $275.97 | $283.48 | 5.63M |
| Oct 13, 2026 | $283.29 | $283.43 | $273.70 | $274.36 | 6.41M |
| Oct 12, 2026 | $277.65 | $281.30 | $276.01 | $281.12 | 5.59M |
| Oct 9, 2026 | $271.53 | $277.60 | $270.38 | $276.47 | 4.3M |
| Oct 8, 2026 | $270.98 | $272.515 | $265.71 | $272.42 | 5.49M |
| Oct 7, 2026 | $268.40 | $274.94 | $266.89 | $271.36 | 6.08M |
Latest ABBV news
The latest Smart Investors Daily articles mentioning ABBV.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ABBV research
Overview
Company profile and research snapshot.
Company profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $258.83
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Guggenheim | Buy | — |
| Nov 2, 2026 | RBC Capital | Outperform | — |
| Nov 2, 2026 | Wells Fargo | Overweight | — |
| Nov 2, 2026 | Canaccord Genuity | Buy | — |
| Nov 2, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
Generated Nov 4, 2026, 9:00 PM
Why Is ABBV Up Today?
AbbVie gained 3.11% today as the pharmaceutical giant continues to execute on strategic acquisitions and pipeline expansion, demonstrating investor confidence in its diversified growth strategy. The stock's strength reflects market appreciation for the company's aggressive moves in high-value therapeutic areas including immunology, neuroscience, and migraine treatment.
Bottom line: AbbVie's 3.11% gain reflects market validation of its two major acquisitions totaling $2.14 billion aimed at fortifying immunology and neuroscience platforms—areas showing robust near-term growth. While analyst ratings remain largely neutral with modest price target increases, the company's strategic focus on premium indications and pipeline progress positions it favorably, though investors should monitor integration execution and patent cliff mitigation closely.
Yahoo · Nov 4, 2026
Was There Any Sign Regeneron Stock Would Run?
For questions about this article or underlying research, email [email protected].
Yahoo · Nov 4, 2026
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Yahoo · Nov 4, 2026
AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera
AbbVie will use the Oxford site to advance treatments for immunological, neurological and oncological diseases.
AI research layers
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. Stock Performance
AbbVie Inc. shares traded at $286.00, reflecting a single-day decline of 1.32% per SID market data. Despite the session pullback, the stock has demonstrated sustained momentum across multiple timeframes, gaining 9.9% over the trailing one-month period and 18.47% over the trailing three months. On an annualized basis, ABBV has returned 23.74% over the past twelve months, significantly outperforming broader market benchmarks. Technical indicators confirm this bullish trend structure: the stock trades well above its 50-day moving average of $269.77 and its 200-day moving average of $238.22, according to Massive/Polygon data. The 14-day relative strength index registers at 67.1, approaching overbought territory but not yet signaling an imminent reversal. AbbVie's beta of 0.334 underscores its historically low volatility relative to the broader market, characteristic of large-cap healthcare names. Average daily trading volume stands at approximately 6.4 million shares.
AbbVie Inc. Valuation Analysis
AbbVie Inc. carries a market capitalization of approximately $410.1 billion, positioning it among the largest healthcare companies globally per SID market data. The stock's trailing price-to-earnings ratio stands at 97.75, an elevated figure that reflects significant non-cash charges and amortization costs related to prior acquisitions, including the Allergan deal. The PEG ratio of 1.25 provides additional context, suggesting the earnings multiple is partially justified by anticipated earnings growth. Notably, AbbVie's price-to-book ratio is negative at -126.33, a direct consequence of accumulated goodwill impairments and substantial share repurchase programs that have driven stockholders' equity into negative territory, according to SEC filings. The company continues to return capital to shareholders through its dividend program, with the current yield at approximately 2.87%. This dividend yield remains attractive within the healthcare sector and reflects AbbVie's status as a Dividend Aristocrat with a long track record of consecutive annual increases.
Smart Money Activity for ABBV
AbbVie Inc. registers a composite smart money score of 54 out of 100, generating a neutral overall signal per SID market data. The component breakdown reveals a bifurcated picture across investor categories. Institutional activity scores a perfect 25 out of 25, indicating robust accumulation by major fund managers as reported in 13F institutional filings. Insider activity also scores strongly at 18 out of 25, supported by two insider purchases and zero insider sales recorded over the past 90 days according to SEC Form 4 filings. These insider buys suggest that company executives maintain confidence in the stock's forward trajectory at current price levels. Conversely, dark pool activity scores a modest 9.8 out of 25, indicating below-average off-exchange buying pressure. Congressional trading activity remains minimal at 1.6 out of 25, suggesting limited recent participation from lawmakers. The divergence between strong institutional and insider conviction versus subdued dark pool and congressional activity produces the aggregate neutral reading, though the insider buying pattern warrants monitoring for potential trend confirmation.
AbbVie Inc. Earnings Outlook
AbbVie Inc. has delivered mixed earnings results across recent reporting periods, according to company earnings reports. In the most recent quarter reported on October 30, the company posted earnings per share of $3.82, surpassing the consensus estimate of $3.77 by $0.05. However, the prior quarter reported on July 31 saw a miss, with actual EPS of $3.65 falling $0.12 below the $3.77 analyst estimate. The April 29 quarter also reflected a slight miss, with EPS of $2.65 compared to the $2.66 consensus. Looking ahead, analysts project EPS of $3.01 for the upcoming quarter with results expected on April 24, per analyst estimates. The sequential improvement from $2.65 to $3.65 and then $3.82 in actual earnings demonstrates a positive trajectory despite occasional estimate misses. This pattern reflects AbbVie's ongoing revenue diversification efforts as the company builds its immunology and oncology franchises beyond the legacy Humira platform.
Wall Street Analyst Ratings for ABBV
Wall Street analysts maintain a uniformly positive stance on AbbVie Inc., with five major firms reiterating bullish ratings on November 2 per SID consensus data. Guggenheim and Canaccord Genuity each maintained Buy ratings, while Wells Fargo and Cantor Fitzgerald reiterated their Overweight designations. RBC Capital also reaffirmed its Outperform rating, according to Wall Street analyst reports. Notably, all five actions represented reiterations of existing positive ratings rather than upgrades, suggesting sustained conviction rather than newly emerging bullishness. No analyst downgrades or neutral initiations appear in the recent coverage cycle. The consensus tilt strongly favors the buy side, reflecting broad confidence in AbbVie's ability to navigate the post-Humira biosimilar landscape through its growing Skyrizi and Rinvoq franchises. The clustering of reiterated ratings around the same date coincides with the company's most recent earnings release, indicating that quarterly results reinforced rather than challenged prevailing analyst theses on the stock's fundamental outlook.
